Abstract
Human multidrug resistance protein 7 (MRP7, ABCC10) is a recently described member of the C family of ATP binding cassette proteins (Cancer Lett162:181–191, 2001). However, neither its biochemical activity nor physiological functions have been determined. Here we report the results of investigations of the in vitro transport properties of MRP7 using membrane vesicles prepared from human embryonic kidney 293 cells transfected with MRP7 expression vector. It is shown that expression of MRP7 is specifically associated with the MgATP-dependent transport of 17β-estradiol-(17-β-d-glucuronide) (E217βG). E217βG transport was saturable, with Km andVmax values of 57.8 ± 15 μM and 53.1 ± 20 pmol/mg/min. By contrast, with E217βG, only modest enhancement of LTC4 transport was observed and transport of several other established substrates of MRP family transporters was not detectable to any extent. In accord with the notion that MRP7 has a bipartite substrate binding pocket composed of sites for anionic and lipophilic moieties, transport of E217βG was susceptible to competitive inhibition by both amphiphiles, such as leukotriene C4(Ki(app), 1.5 μM), glycolithocholate 3-sulfate (Ki(app), 34.2 μM) and MK571 (Ki(app), 28.5 μM), and lipophilic agents such as cyclosporine A (Ki(app), 14.4 μM). Of the inhibitors tested, LTC4 was the most potent, in agreement with the possibility that it is a substrate of the pump. The determination that MRP7 has the facility for mediating the transport of conjugates such as E217βG indicates that it is a lipophilic anion transporter involved in phase III (cellular extrusion) of detoxification.
Footnotes
-
This work was supported in part by National Institutes of Health grants CA73728 (to G.D.K.) and CA06927 to the Fox Chase Cancer Center and by an appropriation from the Commonwealth of Pennsylvania. Z.-S.C. is the recipient of a W. J. Avery Fellowship from Fox Chase Cancer Center and a Japan Research Foundation Award for Clinical Pharmacology. E.H.-B. received fellowship support from National Institutes of Health training grant CA75266.
- Abbreviations:
- MRP
- multidrug resistance protein (MRP1-MRP7, gene symbols ABCC1-ABCC6 and ABCC10)
- MOAT
- multispecific organic anion transporter (MOAT-B, MOAT-C, MOAT-D and MOAT-E are alternative names for MRP4, MRP5, MRP3 and MRP6, respectively, and cMOAT is an alternative name for MRP2)
- LTC4
- leukotriene C4
- DNP-SG, S-(2,4-dinitrophenyl)glutathione
- E217βG, 17β-estradiol 17-(β-d-glucuronide)
- E23SO417βG
- 17β-estradiol 3-sulfate-17-(β-d-glucuronide)
- ABC
- ATP-binding cassette
- HEK
- human embryonic kidney
- MK571
- 3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethyl-amino-3-oxopropyl)-thio}-methyl]thio)propanoic acid
- PSC833
- 3-oxo-4-butenyl-4-methyl-(Thr1)-(Val2)-cyclosporin
- Received June 13, 2002.
- Accepted November 5, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|